lumos pharma is an clinical stage biotechnology company focused on developing therapeutics for rare diseases
Company profile
Ticker
LUMO
Exchange
Website
CEO
Richard J. Hawkins
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
NEWLINK GENETICS CORP
SEC CIK
Corporate docs
Subsidiaries
NewLink International • BlueLink Pharmaceuticals, Inc • BioProtection Systems Corporation • Lumos Pharma Sub, Inc. ...
IRS number
421491350
LUMO stock data
Latest filings (excl ownership)
8-K
Lumos Pharma Announces that the USPTO Has Granted Patent Protection for Novel Formulation of LUM-201, Extending Exclusivity to 2042
20 Mar 24
10-K
2023 FY
Annual report
7 Mar 24
8-K
Lumos Pharma Reports Full Year 2023 Financial Results and Provides Clinical Development Update
7 Mar 24
8-K
Regulation FD Disclosure
4 Jan 24
8-K
Other Events
15 Nov 23
10-Q
2023 Q3
Quarterly report
7 Nov 23
8-K
Lumos Pharma Reports Third Quarter 2023 Financial Results and Clinical Development Updates
7 Nov 23
8-K
Lumos Pharma Announces Topline Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials of LUM-201 in PGHD
7 Nov 23
8-K
Lumos Pharma Announces New Data and Analysis of 15 Subjects from OraGrowtH212 Trial Presented at the 2023 ESPE Annual Meeting
26 Sep 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
Transcripts
LUMO
Earnings call transcript
2023 Q2
9 Aug 23
LUMO
Earnings call transcript
2023 Q1
3 May 23
LUMO
Earnings call transcript
2022 Q4
1 Mar 23
LUMO
Earnings call transcript
2022 Q3
14 Nov 22
LUMO
Earnings call transcript
2022 Q2
10 Aug 22
LUMO
Earnings call transcript
2022 Q1
11 May 22
LUMO
Earnings call transcript
2021 Q4
11 Mar 22
LUMO
Earnings call transcript
2021 Q3
4 Nov 21
LUMO
Earnings call transcript
2021 Q2
5 Aug 21
LUMO
Earnings call transcript
2021 Q1
6 May 21
Latest ownership filings
SC 13G/A
GOLDMAN SACHS GROUP INC
9 Feb 24
4
John C. McKew
7 Feb 24
144
Notice of proposed sale of securities
6 Feb 24
SC 13G
WELLS FARGO & COMPANY/MN
6 Feb 24
4
John C. McKew
5 Feb 24
4
Richard J Hawkins
5 Feb 24
4
Lori D Lawley
5 Feb 24
4
Aaron Schuchart
5 Feb 24
4
BRADLEY J POWERS
5 Feb 24
3
Pisit Duke Pitukcheewanont
10 Jan 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 35.56 mm | 35.56 mm | 35.56 mm | 35.56 mm | 35.56 mm | 35.56 mm |
Cash burn (monthly) | 768.33 k | 3.18 mm | 2.98 mm | 2.95 mm | 2.61 mm | 2.46 mm |
Cash used (since last report) | 4.59 mm | 18.99 mm | 17.80 mm | 17.66 mm | 15.59 mm | 14.72 mm |
Cash remaining | 30.96 mm | 16.57 mm | 17.75 mm | 17.89 mm | 19.97 mm | 20.84 mm |
Runway (months of cash) | 40.3 | 5.2 | 6.0 | 6.1 | 7.7 | 8.5 |
Institutional ownership, Q3 2023
40.4% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 35 |
Opened positions | 2 |
Closed positions | 2 |
Increased positions | 7 |
Reduced positions | 12 |
13F shares | Current |
---|---|
Total value | 7.06 bn |
Total shares | 3.28 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
SHV Management Services II | 676.83 k | $6.06 mm |
BX Blackstone | 468.15 k | $1.54 bn |
WFC Wells Fargo & Co. | 416.55 k | $1.37 bn |
GS Goldman Sachs | 406.56 k | $1.34 bn |
Vanguard | 235.44 k | $776.94 mm |
Renaissance Technologies | 226.71 k | $748.00 k |
Flynn James E | 161.71 k | $2.24 mm |
Acuitas Investments | 125.24 k | $413.30 mm |
JEF Jefferies Financial | 120.65 k | $398.15 mm |
Lion Point Capital | 90.79 k | $299.62 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
6 Feb 24 | John C. McKew | Common Stock | Sell | Dispose S | No | Yes | 3.032 | 438 | 1.33 k | 18,403 |
1 Feb 24 | Powers Bradley J | Common Stock | Payment of exercise | Dispose F | No | No | 3.01 | 240 | 722.40 | 5,749 |
1 Feb 24 | Lawley Lori D | Common Stock | Payment of exercise | Dispose F | No | No | 3.01 | 215 | 647.15 | 11,787 |
1 Feb 24 | Aaron Schuchart | Common Stock | Payment of exercise | Dispose F | No | No | 3.01 | 202 | 608.02 | 5,679 |
1 Feb 24 | Hawkins Richard J | Common Stock | Payment of exercise | Dispose F | No | No | 3.01 | 690 | 2.08 k | 750,115 |
News
HC Wainwright & Co. Reiterates Buy on Lumos Pharma, Maintains $28 Price Target
20 Mar 24
Oppenheimer Maintains Outperform on Lumos Pharma, Maintains $16 Price Target
8 Mar 24
HC Wainwright & Co. Reiterates Buy on Lumos Pharma, Maintains $28 Price Target
8 Mar 24
Lumos Pharma: Q4 Earnings Insights
7 Mar 24
Lumos Pharma Q4 2023 GAAP EPS $(1.170) Misses $(1.150) Estimate, Sales $826.000K Beat $1.750K Estimate
7 Mar 24
Press releases
Lumos Pharma Announces that the USPTO Has Granted Patent Protection for Novel Formulation of LUM-201, Extending Exclusivity to 2042
20 Mar 24
Lumos Pharma Reports Full Year 2023 Financial Results and Provides Clinical Development Update
7 Mar 24
Lumos Pharma to Participate in Oppenheimer's 34th Annual Healthcare Life Sciences Conference
5 Feb 24
Lumos Pharma Promotes Pisit "Duke" Pitukcheewanont, MD to Chief Medical Officer
4 Jan 24